Valuation: Celldex Therapeutics, Inc.

Market Cap 3.26B 2.83B 2.65B 2.42B 4.58B 311B 4.64B 31.01B 12.17B 155B 12.25B 11.98B 517B P/E 2026 *
-10x
P/E 2027 * -9.69x
Enterprise Value 2.68B 2.33B 2.18B 1.99B 3.76B 255B 3.81B 25.48B 10B 128B 10.06B 9.85B 425B EV / Sales 2026 *
1,073x
EV / Sales 2027 * 287x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celldex Therapeutics, Inc.

Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.26B
+2.08%+2.77%+5.09%+17.87% 48.7B
+0.26%+2.93%+439.43%+533.80% 42.05B
-1.53%-2.25%+30.95%+7.15% 38.26B
+0.69%+2.40%+10.48%+63.05% 37.5B
+2.47%+2.63%+14.71%+48.37% 31.44B
-0.47%+1.16%+35.93%+126.09% 16.33B
+2.31%-0.49% - - 16.47B
+0.74%+3.29%+7.15%+19.89% 13.98B
-1.43%-2.63%+3.70%-36.38% 12.43B
Average +0.57%+0.76%+68.43%+97.48% 28.57B
Weighted average by Cap. +0.70%+0.94%+89.33%+121.99%

Financials

2026 *2027 *
Net sales 2.5M 2.17M 2.03M 1.86M 3.51M 238M 3.55M 23.75M 9.32M 119M 9.38M 9.18M 396M 9.51M 8.26M 7.73M 7.07M 13.35M 906M 13.52M 90.44M 35.49M 453M 35.72M 34.94M 1.51B
Net income -320M -278M -260M -238M -449M -30.5B -455M -3.04B -1.19B -15.24B -1.2B -1.18B -50.73B -365M -316M -296M -271M -512M -34.74B -518M -3.47B -1.36B -17.36B -1.37B -1.34B -57.77B
Net Debt -581M -505M -472M -432M -816M -55.39B -827M -5.53B -2.17B -27.67B -2.18B -2.14B -92.11B -527M -457M -428M -392M -740M -50.2B -749M -5.01B -1.97B -25.08B -1.98B -1.94B -83.48B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
41.56USD
Average target price
57.07USD
Spread / Average Target
+37.31%

Quarterly revenue - Rate of surprise